Episode 8 · August 28, 2023 · 31 min

8: QT Prolongation Guidance ICH E14 (Ep. 8)

Speed

This episode is a discussion of the FDA and ICH guidance E14 titled “Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs”. I start with background on the reason for these evaluations, then move to an overview of the key evaluations needed. I then discuss in some detail the thorough QT study and the concentration QT analysis. Then I provide some parting thoughts from my experiences with these analyses.

Links discussed in the show:

• ICH E14 Guidance (FDA website)

• Scientific white paper on concentration – QTc modeling by Garnett et. al

• Correction to publication

• You can connect with me on LinkedIn and send me a message ()

• Send me a message

• Sign up for my newsletter

Related episodes

Ep 14Nov 27, 202320 min

Clinical Drug Interaction Studies (Ep. 14)

In today’s episode I covered the different types of drug interactions, followed by features of clinical drug evaluation studies recommended in the guidance. Then I will review recommendations for…

Ep 10Sep 25, 202325 min

Exposure-Response FDA Guidance (Ep. 10)

This episode is a discussion of the FDA guidance “Exposure-Response Relationships”. The relationship between drug exposure and response is critical to any determination of the safety and…

Ep 11Oct 9, 202331 min

Model diagnostics and selection (Ep. 11)

This episode is a discussion on model evaluation and selection. I discussed diagnostic plots using predictions and residuals. I covered approaches for model selection and factors to consider. The…

8: QT Prolongation Guidance ICH E14 (Ep. 8)

Related episodes

Clinical Drug Interaction Studies (Ep. 14)

Exposure-Response FDA Guidance (Ep. 10)

Model diagnostics and selection (Ep. 11)

Never miss an episode